MARKET

GLYC

GLYC

Glycomimetics
NASDAQ
0.2823
+0.0069
+2.51%
Closed 19:47 05/22 EDT
OPEN
0.2800
PREV CLOSE
0.2754
HIGH
0.2920
LOW
0.2706
VOLUME
960.08K
TURNOVER
0
52 WEEK HIGH
3.530
52 WEEK LOW
0.2560
MARKET CAP
18.20M
P/E (TTM)
-0.4875
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at GLYC last week (0513-0517)?
Weekly Report · 3d ago
Weekly Report: what happened at GLYC last week (0506-0510)?
Weekly Report · 05/13 12:04
Glycomimetics, Inc. Form 10-Q for the Quarterly Period Ended March 31, 2024
Press release · 05/11 03:00
GlycoMimetics GAAP EPS of -$0.17 in-line
GlycoMimetics GAAP EPS of -$0.17 in-line. As of March 31, 2024, the company had $31.3 million in cash and cash equivalents. The company expects to fund operating expenses and capital expenditure through the fourth quarter of 2024.
Seeking Alpha · 05/10 06:25
GlycoMimetics: Q1 Earnings Snapshot
GlycoMimetics Inc. Reported a loss of $10.7 million in its first quarter. The Rockville, Maryland-based company said it had a lost of 17 cents per share. The results did not meet Wall Street expectations for the company's results.
Barchart · 05/09 18:19
Notable earnings before Thursday's open
Seeking Alpha · 05/08 16:34
GlycoMimetics Inc <GLYC.OQ> expected to post a loss of 16 cents a share - Earnings Preview
GlycoMimetics Inc expected to post a loss of 16 cents a share. The company is expected to show change in quarterly revenue when it reports results on May 9 for the period ending March 31 2024. The average analyst rating on the shares is "buy"
Reuters · 05/07 18:28
GLYCOMIMETICS INC <GLYC.O>: JEFFERIES CUTS TARGET PRICE TO $1 FROM $3
Reuters · 05/07 04:14
More
About GLYC
GlycoMimetics, Inc. is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and for inflammatory diseases. It is developing a pipeline of glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in biological processes, to inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection. Its drug candidates include Uproleselan, GMI-1687, Galectin Antagonists and GMI-1359. It is developing Uproleselan, a specific E-selectin antagonist, to be used in combination with chemotherapy to treat patients with AML, a life-threatening hematologic cancer, and potentially other hematologic cancers. It has designed an antagonist of E-selectin, GMI-1687, that is suitable for subcutaneous administration. GMI-1359 is a drug candidate that simultaneously targets both E-selectin and a chemokine receptor (CXCR4).

Webull offers GlycoMimetics Inc stock information, including NASDAQ: GLYC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GLYC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GLYC stock methods without spending real money on the virtual paper trading platform.